U.S. FDA Removes Suicide Warnings from Popular GLP-1 Weight-Loss Medications: What Patients Should Know

Recent announcements from U.S. regulators have brought important clarity to patients using — or considering — popular GLP-1 weight-loss medications such as Wegovy, Saxenda, and Zepbound.

On January 14, 2026, the U.S. Food and Drug Administration (FDA) formally instructed drug manufacturers Novo Nordisk and Eli Lilly to remove label warnings related to potential suicidal thoughts or behaviors from their blockbuster obesity medications. This decision follows an extensive and comprehensive safety review by federal regulators.

What Did the FDA Find?

According to the FDA, a detailed analysis of available clinical trial data, post-marketing surveillance, and real-world evidence found no increased risk of suicide or suicidal behavior associated with GLP-1 receptor agonists used for weight management.

Earlier, in January 2024, regulators had reported no clear link but noted they could not fully exclude a small theoretical risk. The latest review has now put those concerns to rest.

Importantly, the FDA also highlighted that GLP-1 medications used for diabetes treatment have never carried suicide warnings, reinforcing the consistency of the new labeling decision.

“Today’s FDA action will ensure consistent messaging across the labeling for all FDA-approved GLP-1 receptor agonist medications,” the agency stated.

What Does This Mean for Patients in Canada?

While this announcement comes from the United States, it is highly relevant for Canadian patients. Health Canada continues to monitor GLP-1 receptor agonists closely, and Canadian healthcare providers rely on international safety data when counseling patients.

At Centrum Pharmacy, we emphasize that medication safety is dynamic and evidence-based. Regulatory decisions evolve as higher-quality data becomes available — and this FDA update reflects growing confidence in the overall safety profile of GLP-1 therapies when appropriately prescribed and monitored.

The Role of Pharmacist-Led Counselling

GLP-1 medications are powerful tools — but they are not “one-size-fits-all” solutions.

At Centrum Pharmacy, our pharmacists provide structured, individualized counselling for patients using GLP-1 receptor agonists, including:

• Reviewing mental health history and current medications
• Monitoring for known side effects such as nausea, dehydration, and gastrointestinal symptoms
• Reinforcing realistic expectations around weight loss and metabolic health
• Coordinating care with family physicians at Orleans Family Health Clinic, ensuring patients receive connected, physician-led follow-up

This approach reflects our commitment to the 4 C’s of care:
Complete, Comprehensive, Caring, and Connected Care.

The Bottom Line

The FDA’s decision to remove suicide warnings from GLP-1 weight-loss medications is reassuring for patients and providers alike. It underscores the importance of evidence-based regulation, ongoing surveillance, and — most importantly — professional guidance.

If you are using or considering a GLP-1 medication for weight management or diabetes, speak with a pharmacist at Centrum Pharmacy. We are here to ensure your treatment is safe, appropriate, and fully supported within a broader healthcare team.

Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.